-
Study aim
-
To compare the efficacy and safety of oral tranexamic acid with intradermal tranexamic acid mesotherapy in women with melasma.
-
Design
-
A parallel-group randomized clinical trial with 1:1 allocation using a random number table.
-
Settings and conduct
-
Eligible participants will be evaluated at baseline and followed during treatment and the post-treatment follow-up period. Clinical assessment will be performed using the modified Melasma Area and Severity Index (mMASI), MELASQoL, and standardized facial imaging with VisioFace and DermLite 4
-
Participants/Inclusion and exclusion criteria
-
Women aged 18–45 years with clinically diagnosed melasma and Fitzpatrick skin phototypes I–IV will be enrolled. Exclusion criteria include a history of venous or arterial thrombosis, thromboembolic disorders or predisposition to thrombosis, significant coagulation disorders, concomitant medications affecting coagulation that may make participation inappropriate, pregnancy or breastfeeding, known hypersensitivity to tranexamic acid, severe renal disease or significant renal impairment, history of seizures, severe systemic conditions that may interfere with study participation or safety assessment, active skin disease at the injection site, and recent treatments for melasma that may interfere with treatment response.
-
Intervention groups
-
Participants two treatment groups. oral tranexamic acid group will receive tranexamic acid 250 mg twice daily for 12 weeks. The intradermal tranexamic acid mesotherapy group will receive intradermal tranexamic acid injections every 2 weeks for 12 weeks.participants will receive sunscreen SPF 50 and standardized sun-avoidance advice.
-
Main outcome variables
-
change in mMASI score from baseline to 12 weeks after treatment initiation. visual analogue scale (VAS), recurrence of melasma during the 3-month post-treatment follow-up period, and treatment-related adverse events.